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SodiumBackground: The prevalence, the clinical characteristics and the impact of hyponatremia on the prognosis of pa-
tients with chronic heart failure secondary to Chagas cardiomyopathy is unknown.
Methods: All patients with positive serology for Chagas disease and a left ventricular ejection fraction b55% on echo-
cardiography routinely followed at the cardiomyopathy service of the university hospital from January, 2000 to
December, 2008 were screened. The work-up consisted of anamnesis, physical examination, standard laboratory tests,
12-lead resting ECG, and 2-D echocardiography. Hyponatremia was deﬁned as serum sodium levels b135 mEq/L.
Results: 246 patientswere entered in the study; 30 (12%) patients were found to have hyponatremia. Amultivariate
stepwise logistic regression analysis revealed that the need of inotropic support [hazard ratio (HR)=2.97; 95%Con-
ﬁdence Interval (CI) 1.24 to 7,18; p = 0.01], left ventricular systolic diameter (HR = 1.05; 95% CI 1.0 to 1.1, p =
0.03), and diastolic blood pressure (HR: 0,96; 95% CI 0,92 to 0,99; p = 0.04) were independent predictors of
hyponatremia. A Cox regression analysis showed that the need of inotropic support (HR = 1,84; 95% CI 1,24 to
2,72; p = 0,0002), hyponatremia (HR = 2,05; 95% CI 1,25 to 3,38; p = 0.005), Betablocker therapy (hazard
ratio = 0,33; 95% Conﬁdence Interval 0,22 to 0,50; p b 0,0005), and digoxin use (HR = 2,79; 95% CI 1,42 to 5,46;
p = 0003) were independent predictors of all-cause mortality.
Conclusion: Hyponatremia is an independent predictor of all-cause mortality of patients with chronic heart failure
secondary to Chagas cardiomyopathy in the contemporary era of syndrome management. Hyponatremia can be
predicted by variables consistent with syndrome severity.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In the 21st century, Chagas disease still is a major health problem in
Latin America, where about 10million people are carriers of the disease,
and about 10,000 people die of the disease annually [1]. Owing to inter-
national immigration, Chagas disease has spread throughout the world,
and the global costs associatedwith this disease are about US 7, 2 billion
each year, higher than that observed in several types of cancer [2].
The disease is caused by Trypanosoma cruzi, a protozoan transmitted
to humans through the feces of a sucking bug. Infection usually occurs in
infancy. Many years later on, about 30% of infected patients develop
chronic cardiomyopathy. Ventricular dysrhythmias, conduction disturbances,4, Ribeirão Preto city, Zip Code:
eliability and freedom from bias
. This is an open access article undersudden cardiac death [3], chronic systolic heart failure [4] cardiac
thrombosis [5], thromboembolism [6], and precordial chest pain [7]
are the protean clinical manifestations of the disease.
Chronic heart failure secondary to Chagas cardiomyopathy has a dis-
mal prognosis not only in patients with moderate heart failure [8], but
also in patients awaiting heart transplantation [9]. Its outcome is poorer
than that observed in patients with ischemic cardiomyopathy [10], hy-
pertensive cardiomyopathy [11], and idiopathic dilated cardiomyopa-
thy [12,13].
Hyponatremia can be found in about 7% to 20% of outpatients with
chronic non-Chagas disease heart failure [14–17]. NewYorkHeart Associ-
ation Class, higher urea serum levels, treatment with diuretics, and lower
systolic blood pressure have all independently been associated with
hyponatremia in non-Chagas disease heart failure [15]. Hyponatremia
overshadows the outcome of patients with chronic non-Chagas disease
heart failure [15,18].
Plasma serum levels are one of the independent predictors of all
cause-mortality for patients with chronic systolic heart failure secondary
to Chagas cardiomyopathy [8]. The prevalence, the clinical characteristicsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics of patients with chronic systolic heart failure due to Chagas cardio-
myopathy with (n = 30) and without hyponatremia (n = 216).
Variable Hyponatremia No Hyponatremia
Age (years) 53 ± 13 55 ± 14
Male 20 (67%) 141 (67%)
Class III/IV 17 (57%) 61 (28%)⁎
Hospitalization 26 (87%) 129 (60%)⁎⁎
Inotropic support 17 (57%) 51 (24%)⁎⁎⁎
ACEI/ARB 29 (97%) 200 (93%)
Betablockers 10 (33%) 118 (55%)⁎⁎⁎⁎
Digoxin 28 (93%) 148 (68%)#
Diuretics 26 (87%) 177 (82%)
Spironolactone 26 (87%) 139 (64%)##
Amiodarone 14 (47%) 83 (38%)
Heart Rate (beats/min) 74 ± 20 70 ± 14
SBP (mmHg) 100 ± 13,4 108.7 ± 16.4
DBP (mmHg) 65 ± 8.6 71.4 ± 11.2###
K (mEq/L) 4.4 ± 0.7 4.4 ± 0.6
Creatinine (mg/dL) 1.4 ± 0.6 1.2 ± 0.4
Hemoglobin (g/L) 13.8 ± 1.7 13.4 ± 1.6
ACEI/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor block; HR =
heart rate; SBP = systolic blood pressure; and DBP = diastolic blood pressure.
⁎ P = 0.02.
⁎⁎ P = 0.004.
⁎⁎⁎ P b 0.001.
⁎⁎⁎⁎ P = 0.03.
# P = 0.005.
## P = 0.01.
### P = 0.01.
Table 2
Electrocardiographic and echocardiographic ﬁndings in patients with chronic systolic
heart failure due to Chagas cardiomyopathy with (n = 30) and without (n = 216)
hyponatremia.
Variable Hyponatremia No hyponatremia
Electrocardiography
Atrial Fibrillation 9 (30%) 60 (28%)
Pacemaker 17 (57%) 107 (49%)
LBBB 7 (23%) 34 (16%)
RBBB 10 (33%) 89 (41%)
LAFB 14 (47%) 85 (39%)
Low Voltage of QRS 1 (3%) 11 (5%)
VPC 19 (63%) 94 (43%)⁎
2D-Echocardiography
WMA 8 (27%) 83 (38%)
LVEF b35% 21 (70%) 92 (43%)⁎⁎
LVDD (mm) 69.9 ± 9.9 63.8 ± 8.5⁎⁎⁎
LVSD (mm) 60.3 ± 10.7 52.6 ± 10.1⁎⁎⁎
RVD (mm) 29,7 ± 7.7 24.9 ± 7.3#
LVEF (%) 28.9 ± 10.2 36.1 ± 13##
LBBB= left bundle branch block; RBBB= right bundle branch block; LAFB= left anterior
fascicular block; VPC = ventricular premature contraction; WMA= wall motion abnor-
malities; LVEF= left ventricular ejection fraction; LVDD= left ventricular diastolic diam-
eter; LVSD = left ventricular systolic diameter; and RVD= right ventricular diameter.
⁎ P = 0.04.
⁎⁎ P = 0.01.
⁎⁎⁎ P b 0.01.
# P b 0.05.
## P = 0.04.
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with this condition is unknown at this time. Accordingly, the present
study was undertaken to clarify the clinical aspects of hyponatremia in
patients with chronic systolic heart failure secondary to Chagas
cardiomyopathy.
2. Methods
2.1. Patients
All patients with positive serology for Chagas disease and a left ven-
tricular ejection fraction b55% on echocardiography routinely followed
at the cardiomyopathy service of the university hospital from January,
2000 to December, 2008 were screened for potentially taking part in
the investigation. Patients with a concomitant disease that could poten-
tially cause heart disease by itself were excluded.
The work-up consisted of anamnesis, physical examination, stan-
dard laboratory tests, 12-lead resting ECG, and 2-D echocardiography.
New York Heart Association functional Class (NYHA), heart rate, and
systemic arterial pressure were observed at study entry. Hyponatremia
was deﬁned as serum sodium levels b135 mEq/L, as previously
established in the MAGGIC study [18].
All patients received evidence-based treatment for chronic systolic
heart failure, according to international guidelines of the time. Thus,
treatmentwith angiotensin converting enzyme inhibitors (ACEI)/angio-
tensin receptor blocks (ARB) and Betablockers (BB) at targeted or max-
imal tolerated doses was considered for all patients. Those with pitting
edema received furosemide, while those in the NYHA Class III/IV with a
left ventricular ejection fraction b30% were treated with digoxin.
Patients usually visited the outpatient service each 4 months, and a
senior heart failure specialist (RBB) supervised the treatment given. Pa-
tients were followed until the close study; they were also censored at
heart transplantation or death.
2.2. Statistical analysis
Continuous variables are presented as mean ± standard deviation,
whereas categorical variables are given as number (percentages). Con-
tinuous variables were compared by the unpaired T-test, while categor-
ical variables were compared by Fisher exact test. The Spearman test
was used to establish correlation between continuous variables. A Cox
proportional hazards model was used to evaluate the ability of
hyponatremia to independently predict all-cause mortality.
In themultivariablemodel, only variableswith a p value b0.05 in the
univariate model were entered a forward stepwise approach to estab-
lish independent predictors of mortality. In addition, continuous vari-
ables underwent the Spearman test to establish correlation among
them. The variable who correlated with others and with the highest
Wald coefﬁcient remained in the model, whereas the other were ruled
out. Thus, each variable entered the multivariable model in a propor-
tional to 10 events in an attempt to avoid overﬁtting.
A separate binary logistic stepwise regression analysis was used to
determine independent variables associated with hyponatremia. Sur-
vival probabilities were estimated by the Kaplan–Meir method. A p
value b0.05 was considered statistically signiﬁcant in all circumstances.
3. Results
A total of 246 patients fulﬁlled the inclusion criteria and were en-
tered in the study. About 30 (12%) patients were found to have
hyponatremia. Table 1 shows the clinical characteristics, whereas
Table 2 gives the electrocardiographic and echocardiographic features
of patients with and without hyponatremia. In comparison to patients
without hyponatremia, patients with hyponatremia had clinical signs
compatible withmore severe chronic heart failure. In fact, such patients
were found to have higher NYHA Class III/IV at presentation, more needof inotropic support, more need of hospitalization to compensate for
acute HF, a lower proportion of patients on Betablockers; a higher pro-
portion of patients on digoxin, diuretics, and spironolactone. Further-
more, they had lower systemic blood pressure at admission, higher
creatinine serum levels, higher frequency of ventricular premature con-
tractions in the 12-lead ECG, larger diastolic and systolic left ventricular
diameters, larger diameter of the right ventricle, and lower left ventric-
ular ejection fraction than patients with no hyponatremia did.
Amultivariate stepwise logistic regression analysis revealed that the
need of inotropic support (hazard ratio= 2.97; 95% Conﬁdence Interval
1.24 to 7.18; p = 0.01), left ventricular systolic diameter (hazard
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blood pressure (hazard ratio: 0.96; 95%Conﬁdence Interval 0.92 to 0.99;
p = 0.04) were independent predictors of hyponatremia.
A Cox regression analysis showed that the need of inotropic support
(hazard ratio=1.84; 95%Conﬁdence Interval 1.24 to 2.72; p=0.0002),
hyponatremia (hazard ratio = 2.05; 95% Conﬁdence Interval 1.25 to
3.38; p = 0.005), Betablocker therapy (hazard ratio = 0.33; 95% Conﬁ-
dence Interval 0.22 to 0.50; p b 0.0005), and digoxin use (hazard
ratio = 2.79; 95% Conﬁdence Interval 1.42 to 5.46; p = 0003) were in-
dependent predictors of all-cause mortality for patients with CHF sec-
ondary to Chagas cardiomyopathy.
Survival analysis revealed that the probability of survival at 12, 24,
37, and 42months of follow-up for Chagas disease heart failure patients
with hyponatremia were 52%, 26%, 21%, and 14%, respectively, and to
those without hyponatremia 82%, 66%, 53%, and 50%, respectively (p b
0,05). Fig. 1 illustrates these data.
4. Discussion
The results of this study conﬁrm and expand our previous ﬁndings
that hyponatremia is an independent predictor of all-cause mortality
for patients with chronic systolic heart failure secondary to Chagas car-
diomyopathy in the current era of heart failure therapy. This is similar to
that is seen in patients with chronic systolic heart failure not associated
with Chagas cardiomyopathy. Furthermore, our study also shows that
hyponatremia is independently associatedwith other variables of prog-
nostic signiﬁcance.
The prevalence of hyponatremia in our study population (12%) was
very similar to that observed in ambulant patients with chronic non-
Chagas disease heart failure [14–17]. This suggests that similar mecha-
nisms of induction of hyponatremia operate in Chagas and non-
Chagas cardiomyopathy patients with chronic heart failure. As expect-
ed, the prevalence of hyponatremia detected in this study was lower
than that observed in non-Chagas disease acute heart failure patients
(usually 20%), for patients with acute heart failure have more severe
myocardial compromise and activation of the Renin Angiotensin Aldo-
sterone System (RAAS) and Autonomic Nervous System (ANS) than pa-
tients with chronic heart failure [19].
Themechanismof hyponatremia in patientswith chronic heart failure
not associated with Chagas cardiomyopathy is multifactorial, but primar-
ily associated withmarked activation of the RAAS and of the ANS. The ac-
tivation of such systems culminates in hypervolemic hypotonic
(dilutional) hyponatremia [20]. Perhaps, the same mechanism may in-
duce hyponatremia in patients with chronic heart failure secondary toFig. 1. Survival probability of Chagas disease patients with CHF with and without
hyponatremia.Chagas cardiomyopathy. In fact, the RAAS has been found to be activated
in patientswith this condition similarly towhat occurs in non-Chagas dis-
ease heart failure [21]. Moreover, the ANS has also been similarly
overactivated in patients with chronic Chagas disease heart failure [22].
Taken together, therefore, such ﬁndings suggest a role for the RAAS and
the ANS in the pathogenesis of hyponatremia in patients with chronic
heart failure secondary to Chagas cardiomyopathy.
Inotropic support was independently associated with hyponatremia
in our investigation. This probably reﬂects the gravity of our study pop-
ulation in which about one third of patients needed inotropic support
during follow-up. In fact, hyponatremiamay appear as the consequence
ofmarked activation of the RAAS and ANS, which ultimately determines
myocyte death, reparative ﬁbrosis, and ventricular remodeling [23,24].
Therefore, this may account, at least in part, for the ability of inotropic
support to predict hyponatremia in patients with chronic heart failure
secondary to Chagas cardiomyopathy.
Left ventricular systolic diameterwas another variable that indepen-
dently predict hyponatremia. Hyponatremia can be the reﬂection of
overactivation of the RAAS and the ANS because of arterial underﬁlling
[25]. This induces a persistent non-osmotic release of arginine-
vasopressin mediated by the RASS and the ANS, culminating in persis-
tent water reabsorption by the nephron collecting ducts [26]. This, in
turn, can lead to increased ventricular preload, thus provokingmyocyte
gap junction dysfunction [16] and ventricular remodeling, expressed by
left ventricular dilatation.
Hyponatremia was also associated with low blood pressure in our
study. A similar ﬁnding has also been observed in patients with chronic
heart failure not associatedwith Chagas cardiomyopathy [15]. This ﬁnd-
ing is consistent with the arterial underﬁlling observed in patients with
chronic heart failure, which, in conjunction with a marked increase in
the post load secondary to overactivation of the RAAS and ANS, induces
low systemic blood pressure. It should be pointed out that almost all pa-
tients with hyponatremia were in use of ACEI/ARB, what may also ex-
plain, at least in part, the low systemic arterial pressure observed in
hyponatremic patients, for patients treatedwith these drugs usually de-
velop a decrease in the systemic pressure [16].
It is interesting to note that diuretic use, which is usually associated
with hyponatremia [14] andmay cause this electrolyte abnormality in pa-
tients with non-Chagas disease heart failure [15], was not a predictor of
hyponatremia in our study. This suggests that the cause of hyponatremia
may be related to the activation of the RAAS and ANS in our patients. An-
other interesting ﬁnding was that Betablocker therapy was not an inde-
pendent predictor of hyponatremia in this study. Betablockers, which
have been found to have a beneﬁcial effect in patients with chronic
heart failure secondary to Chagas cardiomyopathy [27], have been
found to be a predictor of hyponatremia in patients with non-Chagas dis-
ease heart failure [15].The reasons for this discrepancy are unapparent
from this investigation, but may be related to the low systemic arterial
pressure observed in the hyponatremic patients, which may have lead
to low tolerability of Betablockers in the present study.
Plasma serum levels are independent predictors of all-cause mortal-
ity for patients with chronic heart failure not associated with Chagas
disease [28–32]. Hyponatremia has also been found to be an indepen-
dent predictor of all-cause mortality in patients with this condition
[14,16,18]. In patients with chronic heart failure secondary to Chagas
cardiomyopathy, plasma serum levels have been shown to indicate a
poor prognosis for patients with this condition [8]. Our study clearly
shows that hyponatremia is an independent predictor of all-cause mor-
tality for patients with chronic Chagas disease heart failure, thus
expanding our previous data by enrollingmuchmore patients in the co-
hort studied.
Hyponatremia is a modiﬁable risk factor, which can be treated with
ﬂuid restriction or vasopressin V2 receptors blockers. In patients with
acute heart failure, tolvaptan works better than ﬂuid restriction in the
treatment of hyponatremia [33]. Nevertheless, in the EVEREST trial,
tolvaptan did not decreasemortality in patients with acute heart failure
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dressed thequestion of treating hyponatremic patientswith Chagas car-
diomyopathy with chronic systolic heart failure. Therefore, it seems
prudent to treat patients with this condition and hyponatremia, besides
ﬂuid restriction, with targeted doses, or maximal tolerated doses, of
ACEIE/ARB and Betablockers to counteract the deleterious effect of acti-
vation of the RAAS and ANS.
Themain limitation of this investigation is that it was a retrospective
view of a prospective patients' cohort. Therefore, unmeasured factors
may have biased the study. We also did not assess the impact of a serial
measurement of serum sodium levels on prognosis of such patients,
limiting our study to the baseline levels. We did not correlate serum so-
dium levels with serummarkers of the RAAS and ANS,what preclude us
to establish a causal mechanism of hyponatremia with certainty. How-
ever, the data were prospectively collected, and the statistical analysis
performed appears to have avoided the overﬁtting phenomenon, thus
making our data reliable. Besides, our sample size was reasonable, and
patients received evidence-based treatment, thus reﬂecting the every-
day practice of heart failure treatment.
In conclusion, hyponatremia is an independent predictor of all-cause
mortality of patients with chronic heart failure secondary to Chagas car-
diomyopathy in the contemporary era of syndromemanagement. Vari-
ables consistent with syndrome severity can predict hyponatremia in
patients with this condition.References
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